Skip to main content
Fig. 3 | Respiratory Research

Fig. 3

From: Dual versus monotherapy with bronchodilators in GOLD group B COPD patients according to baseline FEV1 level: a patient-level pooled analysis of phase-3 randomized clinical trials

Fig. 3

Difference between dual therapy vs. monotherapy in the percentage of SGRQ responders. CI confidence interval, GOLD Global initiative for Chronic Obstructive Lung Disease, LABA long-acting beta-2 agonist, LAMA long-acting muscarinic antagonist, SGRQ St. George’s Respiratory Questionnaire

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us